Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer therapy with beta-lapachone.

Arthur B Pardee1, You Zhi Li, Chiang J Li

  • 1Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. pardee@mbcrr.harvard.edu

Current Cancer Drug Targets
|August 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Synthetic Biology Medicine and Bacteria-Based Cancer Therapeutics.

Methods in molecular biology (Clifton, N.J.)·2021
Same author

Virulence of <i>Salmonella enterica</i> Serovar Enteritidis Isolate LN-248-0 and Immune Responses in BALB/c Mice.

Biomedical and environmental sciences : BES·2020
Same author

Two controls of cell proliferation underlie cancer relapse.

Journal of cellular physiology·2018
Same author

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

The lancet. Gastroenterology & hepatology·2018
Same author

The S phase: Beginning, middle, and end: A perspective.

Journal of cellular biochemistry·2018
Same journal

Targeted Chemotherapy of Human Breast Cancer Cells Using Docetaxel-Loaded Nanodroplets Coated with Bovine Serum Albumin and Functionalized with Trastuzumab.

Current cancer drug targets·2026
Same journal

Coordinated Roles of T Cells and Natural Killer Cells in Tumor Immunity.

Current cancer drug targets·2026
Same journal

Multi-omics Signature Predicts Anti-EGFR Therapy Benefit in Colorectal Cancer Liver Metastases: A Multi-center Cohort Study.

Current cancer drug targets·2026
Same journal

Anticancer Effect and Mechanism of Novel c-Myc Inhibitor BP1 on Hepatocellular Carcinoma.

Current cancer drug targets·2026
Same journal

Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Cancer.

Current cancer drug targets·2026
Same journal

Corrigendum to: Migrasomes: A Novel Target for Cancer Treatment.

Current cancer drug targets·2026
See all related articles

Beta-lapachone shows anticancer potential, exhibiting lethality against cancer cells and synergistic effects with Taxol. Its mechanism involves DNA repair inhibition and reactive oxygen species production, independent of p53 and caspase pathways.

Area of Science:

  • Pharmacology and Toxicology
  • Cancer Research
  • Biochemistry

Background:

  • Beta-lapachone, an ortho naphthoquinone derived from medicinal plant extracts, is under investigation for its therapeutic potential.
  • Preliminary studies indicate beta-lapachone's cytotoxicity against various cancer cell lines and efficacy in animal tumor models.

Purpose of the Study:

  • To explore the anticancer properties and potential applications of beta-lapachone.
  • To investigate the synergistic effects of beta-lapachone with conventional chemotherapy agents and radiation.
  • To elucidate the mechanisms underlying beta-lapachone-induced cell death.

Main Methods:

  • In vitro cytotoxicity assays against diverse cancer cell lines.
  • In vivo studies using tumor-bearing animal models.

Related Experiment Videos

  • Investigation of drug interactions, including synergy with Taxol, X-rays, and alkylating agents.
  • Biochemical analyses to identify cellular targets and pathways involved in cell death.

    • Main Results:

    • Beta-lapachone demonstrated significant lethality against cancer cells at micromolar concentrations.
    • Remarkable synergistic lethality was observed between beta-lapachone and Taxol in preclinical models.
    • Beta-lapachone enhanced the efficacy of X-rays and alkylating agents by inhibiting DNA repair.
    • Proposed mechanisms include futile cycling via NAD(P)H: quinone oxidoreductase (NQO1) and reactive oxygen species (ROS) generation, independent of p53 and caspase pathways.

    Conclusions:

    • Beta-lapachone exhibits promising anticancer activity, both as a single agent and in combination therapies.
    • Its ability to inhibit DNA repair and induce cell death through ROS production warrants further clinical investigation.
    • Further research is needed to fully understand the detailed mechanisms of beta-lapachone-induced cell death.